Pheo-Type: A Diagnostic Gene-expression Assay for the Classification of Pheochromocytoma and Paraganglioma
- 1 March 2016
- journal article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 101 (3), 1034-1043
- https://doi.org/10.1210/jc.2015-3889
Abstract
Context: Pheochromocytomas and paragangliomas (PPGLs) are heritable neoplasms that can be classified into gene-expression subtypes corresponding to their underlying specific genetic drivers. Objective: This study aimed to develop a diagnostic and research tool (Pheo-type) capable of classifying PPGL tumors into gene-expression subtypes that could be used to guide and interpret genetic testing, determine surveillance programs, and aid in elucidation of PPGL biology. Design: A compendium of published microarray data representing 205 PPGL tumors was used for the selection of subtype-specific genes that were then translated to the Nanostring gene-expression platform. A support vector machine was trained on the microarray dataset and then tested on an independent Nanostring dataset representing 38 familial and sporadic cases of PPGL of known genotype (RET, NF1, TMEM127, MAX, HRAS, VHL, and SDHx). Different classifier models involving between three and six subtypes were compared for their discrimination potential. Results: A gene set of 46 genes and six endogenous controls was selected representing six known PPGL subtypes; RTK1–3 (RET, NF1, TMEM127, and HRAS), MAX-like, VHL, and SDHx. Of 38 test cases, 34 (90%) were correctly predicted to six subtypes based on the known genotype to gene-expression subtype association. Removal of the RTK2 subtype from training, characterized by an admixture of tumor and normal adrenal cortex, improved the classification accuracy (35/38). Consolidation of RTK and pseudohypoxic PPGL subtypes to four- and then three-class architectures improved the classification accuracy for clinical application. Conclusions: The Pheo-type gene-expression assay is a reliable method for predicting PPGL genotype using routine diagnostic tumor samples.Keywords
This publication has 57 references indexed in Scilit:
- Moving Beyond “Lumpology”: PET/CT Imaging of Pheochromocytoma and ParagangliomaClinical Cancer Research, 2015
- Rare Germline Mutations Identified by Targeted Next-Generation Sequencing of Susceptibility Genes in Pheochromocytoma and ParagangliomaJournal of Clinical Endocrinology & Metabolism, 2014
- Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice GuidelineJournal of Clinical Endocrinology & Metabolism, 2014
- Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneityNature Reviews Cancer, 2014
- Whole exome sequencing is an efficient and sensitive method for detection of germline mutations in patients with phaeochromcytomas and paragangliomasClinical Endocrinology, 2013
- Metastatic Pheochromocytoma and Paraganglioma: Focus on TherapeuticsHormone and Metabolic Research, 2012
- Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomasEndocrine-Related Cancer, 2011
- Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic IndicatorsJournal of Clinical Endocrinology & Metabolism, 2011
- High Frequency ofSDHBGermline Mutations in Patients with Malignant Catecholamine-Producing Paragangliomas: Implications for Genetic TestingJournal of Clinical Endocrinology & Metabolism, 2006
- PhaeochromocytomaThe Lancet, 2005